ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novo Nordisk and Lumos Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Novo NordiskLumos Pharma
studies on the registry1,45442
open to participants now1145
phase 3 studies under way552
reach primary completion within a year630
programswith a study of their own in two years43+14 named only2

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovo NordiskLumos Pharma
Phase 1

Novo Nordisk: 26 of its 43 programs at phase 1

  1. NNC0537-1482phase 1
  2. NNC0442-0344phase 1
  3. NNC0581-0001phase 1
  4. coramitugphase 1
  5. Gastric Inhibitory Polypeptidephase 1

and 21 more — sign in to see them all

60%

Lumos Pharma: 1 of its 2 programs at phase 1

  1. ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATEphase 1
50%
Phase 2

Novo Nordisk: 6 of its 43 programs at phase 2

  1. NNC0662-0419phase 2
  2. UBT251phase 2
  3. CDR132Lphase 2
  4. NNC0519-0130phase 2
  5. zalferminphase 2

and 1 more — sign in to see them all

14%
00%
Phase 3

Novo Nordisk: 7 of its 43 programs at phase 3

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. etavopivatphase 3
  4. ziltivekimabphase 3
  5. efruxiferminphase 3

and 2 more — sign in to see them all

16%

Lumos Pharma: 1 of its 2 programs at phase 3

  1. ibutamorenphase 3
50%
Approved, new studies

Novo Nordisk: 4 of its 43 programs at approved, new studies

  1. Semaglutideapproved, new study
  2. Liraglutideapproved, new study
  3. insulin icodecapproved, new study
  4. recombinant FVIIaapproved, new study
9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novo Nordisk24 readouts · 4 phase 3·

Novo Nordisk, Dec ’26: 4 programs whose next study reaches primary completion

  1. Liraglutideapproved, new study · Dec 13 · NCT07225816
  2. Semaglutideapproved, new study · Dec 13 · NCT07225816
  3. NNC0662-0419phase 2 · Dec 14 · NCT07184632
  4. CDR132Lphase 2 · Dec 31 · NCT07656454

Novo Nordisk, Jan ’27: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. UBT251phase 2 · Jan 14 · NCT07395687
  2. NNC0537-1482phase 1 · Jan 15 · NCT07218627
  3. NNC4004-0002phase 1 · Jan 19 · NCT06859073
  4. NNC6989-0001phase 1 · Jan 21 · NCT07437079
  5. insulin icodecapproved, new study · Jan 25 · NCT07076199

and 3 more — sign in to see them all

Novo Nordisk, Feb ’27: 1 program whose next study reaches primary completion

  1. NNC0442-0344phase 1 · Feb 5 · NCT07220564

Novo Nordisk, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cagrilintidephase 3 · Mar 1 · NCT07011667
·

Novo Nordisk, May ’27: 2 programs whose next study reaches primary completion

  1. NNC4005-001phase 1 · May 14 · NCT07214870
  2. coramitugphase 1 · May 30 · NCT07448623
··

Novo Nordisk, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. NNC0705-0002phase 1 · Aug 1 · NCT07797855
  2. NNC6022-0004phase 1 · Aug 3 · NCT07693868
  3. etavopivatphase 3 · Aug 20 · NCT05953584
  4. recombinant FVIIaapproved, new study · Aug 26 · NCT07157423

Novo Nordisk, Sep ’27: 3 programs whose next study reaches primary completion

  1. NNC0642-1895phase 1 · Sep 12 · NCT07829406
  2. INV-347phase 1 · Sep 15 · NCT07153172
  3. NNC0721-8060phase 1 · Sep 23 · NCT07767175

Novo Nordisk, Oct ’27: 1 program whose next study reaches primary completion

  1. NNC0581-0001phase 1 · Oct 11 · NCT06891365
Lumos Pharma0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novo Nordisk

New programs 5

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Lumos Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionNovo NordiskLumos Pharma
Obesityboth · compare here

Novo Nordisk in Obesity: 19 programs

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. NNC0662-0419phase 2
  4. UBT251phase 2
  5. NNC0519-0130phase 2

and 14 more — sign in to see them all

Their studies: Novo Nordisk’s studies of Obesity in search

Lumos Pharma in Obesity: 1 program

  1. ibutamorenphase 3

Their studies: Lumos Pharma’s studies of Obesity in search

Alzheimer Diseaseboth · compare here

Novo Nordisk in Alzheimer Disease: 1 program

  1. Semaglutideapproved, new study

Their studies: Novo Nordisk’s studies of Alzheimer Disease in search

Lumos Pharma in Alzheimer Disease: 1 program

  1. ibutamorenphase 3

Their studies: Lumos Pharma’s studies of Alzheimer Disease in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Novo Nordisk 17 of 43 · Lumos Pharma 1 of 2 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novo Nordisk: 14).